Understanding the mechanisms of cell cycle checkpoints has led to the development of targeted cancer therapies. For example, inhibitors of CHK1 and CHK2 are being explored to sensitize cancer cells to DNA-damaging agents. Additionally, targeting the p53 pathway is another strategy to induce cell death in cancer cells.
